Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 460 participants.

Also called NCT01068678

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 460 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01068678
  • EudraCT 2009-011398-33
Other papers using this trial's data
  • Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials The lancet. Diabetes & endocrinology, 2013-10 DOI, PubMed 24622318

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Israel, Puerto Rico, Slovakia, South Africa, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01068678. Randomized; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2010-11 (actual). Results posted on 2015-12-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Acronym
BEGIN™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec
Intervention (Drug)
insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01068678
Content hash
990e3ba08cd5b0e477f4ea99050cfeff9bbf9966bf25919e794e6200740f674b